Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.

Endocrinology | 2016

Leptin treatment has beneficial effects on plasma lipids in patients with lipodystrophy, but the underlying mechanism is unknown. Proprotein convertase subtilisin/kexin type 9 (PCSK9) decreases low-density lipoprotein (LDL) clearance, promotes hypercholesterolemia, and has recently emerged as a novel therapeutic target. To determine the effect of leptin on PCSK9, we treated male and female ob/ob mice with leptin for 4 days via sc osmotic pumps (∼24 μg/d). Leptin reduced body weight and food intake in all mice, but the effects of leptin on plasma PCSK9 and lipids differed markedly between the sexes. In male mice, leptin suppressed PCSK9 but had no effect on plasma triglycerides or cholesterol. In female mice, leptin suppressed plasma triglycerides and cholesterol but had no effect on plasma PCSK9. In parallel, we treated female lipodystrophic patients (8 females, ages 5-23 y) with sc metreleptin injections (∼4.4 mg/d) for 4-6 months. In this case, leptin reduced plasma PCSK9 by 26% (298 ± 109 vs 221 ± 102 ng/mL; n = 8; P = .008), and the change in PCSK9 was correlated with a decrease in LDL cholesterol (r(2) = 0.564, P = .03). In summary, in leptin-deficient ob/ob mice, the effects of leptin on PCSK9 and plasma lipids appeared to be independent of one another and strongly modified by sex. On the other hand, in lipodystrophic females, leptin treatment reduced plasma PCSK9 in parallel with LDL cholesterol.

Pubmed ID: 26824363 RIS Download

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: K99 DK100539
  • Agency: NHLBI NIH HHS, United States
    Id: R01HL109650-05
  • Agency: NIDDK NIH HHS, United States
    Id: K12 DK094721
  • Agency: Intramural NIH HHS, United States
  • Agency: NIDDK NIH HHS, United States
    Id: K99DK100539-02
  • Agency: NIDDK NIH HHS, United States
    Id: 5K12DK094721-05
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL109650

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


HMGCR (C-18) (antibody)

RRID:AB_2118199

This polyclonal targets HMGCR

View all literature mentions

SCD1 (E-15) (antibody)

RRID:AB_2183121

This polyclonal targets SCD1 (E-15)

View all literature mentions

Pol II (H-224) (antibody)

RRID:AB_2268548

This polyclonal targets POLR2A

View all literature mentions

Anti-β-Actin Antibody (C4) (antibody)

RRID:AB_626632

This monoclonal targets β-Actin

View all literature mentions

Anti-Acetyl CoA Carboxylase 1, Rabbit mAb (antibody)

RRID:AB_673047

This monoclonal targets Acetyl CoA Carboxylase 1 Rabbit mAb

View all literature mentions

Fatty Acid Synthase antibody (antibody)

RRID:AB_732316

This polyclonal targets Fatty Acid Synthase

View all literature mentions

FDPS antibody (antibody)

RRID:AB_732325

This polyclonal targets Human FDPS

View all literature mentions

normal rabbit IgG (antibody)

RRID:AB_737197

This unknown targets normal rabbit IgG

View all literature mentions

LDL Receptor antibody (antibody)

RRID:AB_881272

This polyclonal targets LDL Receptor antibody

View all literature mentions